Fig. 3From: New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective studyKaplan–Meier analysis estimated CNS relapse-free survival for the 376 patients in the R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) set stratified by independent risk factors. Renal involvement (a), bone involvement (b), and bone marrow (BM) involvement (c) were associated with short CNS relapse-free survivalBack to article page